For patients who cannot tolerate or have contraindications to metformin, a sulfonylurea
is often prescribed as first-line therapy for type 2 diabetes," said Kathleen Dungan, M.
The recently published results, which were included in the company's New Drug Application approved by the FDA in June 2005, were generated from the randomized, double-blind Phase 3 clinical trial comparing treatment with regimens of Glumetza and sulfonylurea
combination therapy to a regimen of sulfonylurea
monotherapy in patients with Type 2 diabetes.
Cardiovascular disease (CVD) events also happened sooner among the sulfonylurea
patients, said Ying Qui, Ph.
Patients who received linagliptin as add-on to metformin and sulfonylurea
with baseline HbA1c greater than or equal to 7.
Among the survey respondents who received oral medications, 52% reported receiving sulfonylureas
The PPAR-gamma agonists, Januvia and Amylin/Eli Lilly's Byetta are each competing for positioning in second- and third-line therapy because of the dominance of generic metformin and sulfonylureas
in earlier lines of treatment.
These active ingredients included sulfonylurea
, dicamba, atrazine, and mesotrione alone or in combination with other herbicides.
The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea
BYETTA is indicated for use as an adjunctive therapy for people with type 2 diabetes who are not achieving blood sugar control using metformin, a sulfonylurea
, or a thiazolidinedione.
In the prospective, multicenter, open-label Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD) trial, funded by Glaxo-SmithKline, the addition of rosiglitazone (Avandia) to either sulfonylurea
or metformin therapy in people with type 2 diabetes increased their risk for heart failure but did not increase the risk of overall cardiovascular morbidity or mortality in a mean follow-up of 5.
CHICAGO, June 24 /PRNewswire-FirstCall/ -- New findings from a retrospective cohort study using real-world claims data of more than 15,000 drug naive patients with type 2 diabetes showed that initial therapy with Avandia(R) (rosiglitazone maleate) was associated with significantly fewer healthcare visits and lower total medical costs when compared to patients initiating therapy with a sulfonylurea
Teva's Glipizide and Metformin Hydrochloride Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Metaglip(R) Tablets, which are indicated as an adjunct to diet and exercise in type 2 diabetes, as initial therapy or as a second-line therapy when response to sulfonylurea
or metformin is inadequate.
5% but still above 7%, either insulin or a sulfonylurea
may be added.
In the OAD group, 16% of patients were treated with metformin plus sulfonylurea
, 27% with a sulfonylurea
alone, and 8% with sulfonylurea
and a DPP-4 inhibitor.
As an insulin secretagogue, sulfonylurea
directly acts on sulfonylurea
receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar's excitation upon insulin release.